AstraZeneca to buy Alexion for $39bn
Tada Images / Shutterstock.com
The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, dapagliflozin, diabetes, Delhi High Court, injunction, patent validity, Torrent Pharmaceutical, Micro Labs, Zydus Healthcare, Eris Lifescience